Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19
Review article
[키워드] accounted
acute infection
acute respiratory syndrome
adjusted
AEs
Analysis
approved
calculate
Clinical studies
Concentration
conducted
coronavirus
coronavirus disease
Course
COVID-19
COVID-19 patient
database
demonstrated
dosages
dose
doses
drug
drugs
EC50
Effects
Efficacy
Endpoint
Evidence
for inclusion
in vitro
India
ingredient
inhibit
initiated
margin
Metrics
nitazoxanide
pandemic
participant
per day
pharmacies
Placebo
Placebo-controlled trials
plasma concentration
Potential treatment
promote
raised
randomised controlled trial
RCT
RCTs
Replication
reported
required
Research
Result
review
Safe
safety profile
SARS-CoV-2
searched
Serious Adverse Event
shown
significant difference
teratogenic
teratogenicity
treat
Treatment
treatments for COVID-19
Trial
trials
[DOI] 10.1016/S2055-6640(20)30017-0 [Article Type] Review article
[DOI] 10.1016/S2055-6640(20)30017-0 [Article Type] Review article